Do Oncologists Believe New Cancer Drugs Offer Good Value?-Reference-Cited by-同舟云学术

Do Oncologists Believe New Cancer Drugs Offer Good Value?

Published:2006-02-01 Issue:2 Volume:11 Page:90-95
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Nadler Eric¹,Eckert Ben²,Neumann Peter J.²

Affiliation:

1. a Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, USA

2. b Tufts-New England Medical Center, Boston, Massachusetts, USA

Abstract

Learning Objectives After completing this course, the reader will be able to: Describe how academic oncologists view the costs of new treatments in their treatment recommendations.Discuss academic oncologists’ perceptions of the cost and benefit of one new treatment in light of published results.Describe how academic oncologists view the cost-effectiveness of new treatments relative to previously accepted standards. CME Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.11-2-90

Reference19 articles.

1. Incremental and average cost-effectiveness ratios: will physicians make a distinction?;Hershey;Risk Anal,2003

2. US neurologists: attitudes on rationing;Holloway;Neurology,2000

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does Real Option Value Influence Oncologists’ Treatment Recommendations? A Survey of US Oncologists;Value in Health;2024-08

2. Institutional design and moral conflict in health care priority-setting;Medicine, Health Care and Philosophy;2024-04-04

3. Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis;Gynecologic Oncology;2023-12

4. Immune checkpoint inhibitor for patients with advanced biliary tract cancer: A cost‐effectiveness analysis;Liver International;2023-08-17

5. SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation;Future Oncology;2023-03-08